NorDiag has fully automated the process from the primary urine tubes to the set up of the BD (Becton Dickinson) ProbeTec ET System. NorDiags “Bullet” instrument has the capacity up to 100 000 isolations per year. The clinical trial has been executed at Ullevaal Universityhospital in Norway.
The trial compared NorDiag’s automated sample preparation solution for sexually transmitted infections with the BD ProbeTec ET Chlamydia trachomatis manual urine sample preparation. The tests were run on the BD ProbeTec ET System and used the BD ProbeTec ET Chlamydia trachomatis Amplified DNA Assay. The results of the clinical study met the criterion.
“This is an important milestone for us since this is the backbone for the IVD/CE marking and successful commercialization of our automated sample preparation systems, says Mårten Wigstøl, CEO in NorDiag. This implies substantial revenue potential for our company towards an established customer base”.
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.
